References
- Bloom H. J. G., Boesen E. Antioestrogens in treatment of breast cancer: Value of Nafoxidine in 52 advanced cases. Brit. med. J. 1974; 2: 7
- Brewin T. B. Clinical experience with Tamoxifen (ICI 46.474) in the management of breast cancer. 8th Int. Congr. of Chemotherapy. Athens 1973, Abstract No. 5274
- Cole M. P., Jones C. T. A., Todd I. D. H. A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46.474. Brit. J. Cancer 1971; 25: 270
- Cole M. P. The treatment of advanced carcinoma of the breast with the antioestrogenic agent Tamoxifen (ICI 46.474). A series of 96 patients. Advanc. antimicrobiol. anti-neoplast. Chemother. 1972; 2: 529
- EORTC Breast Cancer Group: Clinical trial of Nafoxidine, an oestrogen antagonist in advanced breast cancer. Europ. J. Cancer 1972; 8: 387
- Herbst A. L., Griffiths C. T., Kistner R. W. Clomiphene citrate (NSC-35 770) in disseminated mammary carcinoma. Cancer Chemother. Rep. 1964; 43: 39
- Hähnel R., Twaddle E., Ratajczak T. The influence of synthetic antiestrogens on the binding of tritiated estradiol-17β by cytosols of human uterus and human breast carcinoma. J. steroid Biochemistry 1973; 4: 687
- Jordan V. C., Koerner S. Tamoxifen (ICI 46.474) and the human carcinoma 8S oestrogen receptor. Europ. J. Cancer 1975; 11: 205
- Jordan V. C. Effect of ICI 46.474 upon the initiation and growth of 7, 12-dimethylbenz (a) anthracene (DMBA) induced rat mammary carcinoma. Europ. J. Cancer, To be published
- McGuire W. L., Chamness G. C., Costlow M. E., Shepherd R. E. Progress in endocrinology and metabolism. Hormone dependence in breast cancer. Metabolism 1974; 23: 75
- Nissen-Meyer R., Sanner T. The excretion of oestrone, pregnandiol and pregnanetriol in breast cancer patients. Acta endocr. (Kbh.) 1963; 44: 334
- Stoll B. A. Hypothesis: Breast cancer regression under oestrogen therapy. Brit. med. J. 1973; 3: 446
- Ward H. W. C. Anti-oestrogen therapy for breast cancer: A trial of Tamoxifen at two dose levels. Brit. med. J. 1973; 1: 13